Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis

Figures & data

Table 1 Baseline patient features

Age, mean ± SD, years	55.80±15.17
Age of asthma onset, mean ± SD, years	31.10±15.25
Duration of asthma, mean ± SD, years	24.80±13.60
Female sex, n (%)	11 (55)
Weight, mean ± SD, kg	70.20±14.64
Height, mean ± SD, cm	164.6±10.57
BMI, mean ± SD, kg/m^2	26.55±5.68
FEV1, mean ± SD, % predicted	67.80±20.01
FEV1/FVC, mean ± SD, %	69.45±8.92
Atopic subjects, n (%)	14 (70)
Total serum IgE, median (IQR), IU/mL	473.7±669.5

Abbreviations: BMI, body-mass index; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity.

Figure 1 Clinical effects of dupilumab, with regard to ACT score (A), SNOT-22 score (B), and prednisone intake (C). ACT and SNOT-22 values expressed as means ± SD; prednisone intake expressed as medians (IQR). ****p<0.0001.

Figure 2 Functional effects of dupilumab with regard to FEV₁ (A), FVC (B), RV (C), TLC (D), FEF_25–75 (E), and PEF (F). All parameters expressed as means ± SD. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

Figure 3 Effects of dupilumab on biomarkers with regard to FeNO (A), blood eosinophils (B), and blood basophils (C). All parameters expressed as medians (IQR). ****p<0.0001.